
    
      This is an open label single arm Phase II study in patients with progressive SSc. Patients
      will be treated with ABR-215757 for 8 weeks. Assessment of biomarkers, disease activity and
      safety parameters will be performed during treatment. Patients will be offered to continue in
      an open label extension.
    
  